AU2681300A - Solid oral dosage form containing an enhancer - Google Patents

Solid oral dosage form containing an enhancer

Info

Publication number
AU2681300A
AU2681300A AU26813/00A AU2681300A AU2681300A AU 2681300 A AU2681300 A AU 2681300A AU 26813/00 A AU26813/00 A AU 26813/00A AU 2681300 A AU2681300 A AU 2681300A AU 2681300 A AU2681300 A AU 2681300A
Authority
AU
Australia
Prior art keywords
dosage form
enhancer
oral dosage
solid oral
form containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU26813/00A
Other languages
English (en)
Inventor
Kenneth Iain Cumming
Zebunnissa Ramtoola
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elan Corp PLC
Original Assignee
Elan Corp PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Corp PLC filed Critical Elan Corp PLC
Publication of AU2681300A publication Critical patent/AU2681300A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
AU26813/00A 1999-02-22 2000-02-22 Solid oral dosage form containing an enhancer Abandoned AU2681300A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12104899P 1999-02-22 1999-02-22
US60121048 1999-02-22
PCT/GB2000/000628 WO2000050012A1 (en) 1999-02-22 2000-02-22 Solid oral dosage form containing an enhancer

Publications (1)

Publication Number Publication Date
AU2681300A true AU2681300A (en) 2000-09-14

Family

ID=22394170

Family Applications (1)

Application Number Title Priority Date Filing Date
AU26813/00A Abandoned AU2681300A (en) 1999-02-22 2000-02-22 Solid oral dosage form containing an enhancer

Country Status (8)

Country Link
EP (1) EP1154761B1 (https=)
JP (2) JP2002537321A (https=)
AT (1) ATE386508T1 (https=)
AU (1) AU2681300A (https=)
CA (1) CA2363123C (https=)
DE (1) DE60038097T2 (https=)
ES (1) ES2301477T3 (https=)
WO (1) WO2000050012A1 (https=)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6478771B1 (en) 1998-11-13 2002-11-12 Elan Pharma International Limited Drug delivery systems and methods
US7084279B1 (en) 1999-02-11 2006-08-01 Emisphere Technologies Inc. Oxadiazole compounds and compositions for delivering active agents
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
JP2007016034A (ja) * 2000-12-26 2007-01-25 Kirin Brewery Co Ltd 吸収促進剤
JP2004525110A (ja) * 2001-02-16 2004-08-19 清水製薬株式会社 ムコ多糖類製剤およびその製造法
EP1392272B1 (en) * 2001-05-11 2014-08-06 Merrion Research III Limited Permeation enhancers
CA2563533C (en) 2004-04-15 2013-10-01 Shmuel A. Ben-Sasson Compositions capable of facilitating penetration across a biological barrier
AU2014200247B2 (en) * 2004-07-19 2015-05-14 Biocon Limited Insulin-oligomer conjugates, formulations and uses thereof
RU2527893C2 (ru) * 2004-07-19 2014-09-10 Биокон Лимитед Инсулин-олигомерные конъюгаты, их препараты и применения
EP1781257B1 (en) * 2004-08-13 2018-12-19 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
JP4759289B2 (ja) * 2005-03-02 2011-08-31 国立大学法人北海道大学 カルシウム吸収促進組成物およびその利用
BRPI0710503A2 (pt) 2006-04-07 2011-08-16 Merrion Res Iii Ltd uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral
JP2009539862A (ja) * 2006-06-09 2009-11-19 メリオン リサーチ Ｉｉｉ リミテッド 強化剤を含む固体経口投与剤形
EA200970267A1 (ru) * 2006-09-12 2009-08-28 Глэксо Груп Лимитед ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ВКЛЮЧАЮЩАЯ МНОЖЕСТВО МИНИ-ТАБЛЕТОК, СОДЕРЖАЩИХ ИНГИБИТОР ФАКТОРА Xa
RU2453332C2 (ru) * 2007-10-16 2012-06-20 Байокон Лимитид Твердая фармацевтическая композиция (варианты) и способ контроля концентрации глюкозы с ее помощью, способ получения твердой фармацевтической композиции (варианты), таблетка (варианты) и способ получения амфорных частиц
WO2009061805A1 (en) * 2007-11-05 2009-05-14 Scolr Pharma, Inc. Formulations for enhanced bioavailability of orally administered polar agents
RU2517135C2 (ru) * 2008-05-07 2014-05-27 Меррион Рисерч Iii Лимитед Композиции пептидов и способы их получения
KR101814186B1 (ko) 2008-09-17 2018-03-14 키아스마 인코포레이티드 약제학적 조성물 및 연관된 투여방법
GB0904942D0 (en) * 2009-03-23 2009-05-06 Ntnu Technology Transfer As Composition
CA2769633C (en) 2009-07-31 2017-06-06 Thar Pharma, Llc Crystallization method and bioavailability
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
AU2010339907A1 (en) 2009-12-16 2012-07-05 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
US9089484B2 (en) * 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
WO2012071517A2 (en) 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
KR20140046395A (ko) * 2010-12-15 2014-04-18 메리온 리서치 Ⅲ 리미티드 경구 투여를 위한 선택적 인자 ｘａ 억제제의 제약 조성물
SI2651398T1 (en) 2010-12-16 2018-04-30 Novo Nordisk A/S SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND SOL N- (8- (2-HYDROXYBENZOIL) AMINO) CAPRICULATE ACIDS
KR20140026354A (ko) * 2011-01-07 2014-03-05 메리온 리서치 Ⅲ 리미티드 경구 투여용 철의 제약 조성물
PL2696687T3 (pl) 2011-04-12 2017-06-30 Novo Nordisk A/S Pochodne podwójnie acylowanej GLP-1
ES2965469T3 (es) 2012-03-22 2024-04-15 Novo Nordisk As Composiciones que comprenden un agente de suministro y preparación de estas
HRP20181447T1 (hr) 2012-03-22 2018-11-02 Novo Nordisk A/S Pripravci glp-1 peptida i njihova priprava
PT2827845T (pt) 2012-03-22 2019-03-29 Novo Nordisk As Composições compreendendo um agente de entrega e sua preparação
JP6517690B2 (ja) 2012-06-20 2019-05-22 ノヴォ ノルディスク アー／エス ペプチド及び送達剤を含む錠剤製剤
KR102272671B1 (ko) 2013-05-02 2021-07-06 노보 노르디스크 에이/에스 Glp-1 화합물의 경구 투여
JP7211704B2 (ja) 2015-01-29 2023-01-24 ノヴォ ノルディスク アー／エス Ｇｌｐ－１アゴニスト及び腸溶コーティングを含む錠剤
WO2016126830A1 (en) 2015-02-03 2016-08-11 Chiasma Inc. Method of treating diseases
LT3280447T (lt) * 2015-04-08 2019-05-27 Torrent Pharmaceuticals Limited Farmacinės kompozicijos
GB201515387D0 (en) 2015-08-28 2015-10-14 Amazentis Sa Compositions
US10946074B2 (en) 2016-03-03 2021-03-16 Novo Nordisk A/S GLP-1 derivatives and uses thereof
WO2017208070A1 (en) 2016-05-31 2017-12-07 Grünenthal GmbH Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis
MA49617A (fr) 2017-07-19 2020-05-27 Novo Nordisk As Analogues d'egf(a), préparation, formulations et utilisations associées
JP6898518B2 (ja) 2018-02-02 2021-07-07 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アゴニスト、ｎ−（８−（２−ヒドロキシベンゾイル）アミノ）カプリル酸の塩及び滑沢剤を含む固形組成物
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods
JPWO2024143501A1 (https=) * 2022-12-28 2024-07-04

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB953626A (en) * 1961-04-25 1964-03-25 Meito Sangyo Kk Enteric-coated tablets of dextran sulphate ester and method of preparation thereof
US4525339A (en) * 1982-10-15 1985-06-25 Hoffmann-La Roche Inc. Enteric coated oral dosage form
JPS5973600A (ja) * 1982-10-19 1984-04-25 Okayasu Shoten:Kk 排卵誘発剤
DE3331009A1 (de) * 1983-08-27 1985-03-14 Basf Ag, 6700 Ludwigshafen Verfahren zur erhoehung der enteralen resorbierbarkeit von heparin bzw. heparinoiden sowie das so erhaeltliche heparin- bzw. heparinoidpraeparat
ZA898331B (en) * 1988-11-22 1990-07-25 Hoffmann La Roche Pharmaceutical compositions
JPH03275633A (ja) * 1990-03-23 1991-12-06 Teikoku Seiyaku Co Ltd 生理活性ポリペプチドの吸収促進剤
JPH04149126A (ja) 1990-10-09 1992-05-22 Mitsubishi Kasei Corp 経粘膜投与用医薬組成物
IT1245761B (it) * 1991-01-30 1994-10-14 Alfa Wassermann Spa Formulazioni farmaceutiche contenenti glicosaminoglicani assorbibili per via orale.
AU653026B2 (en) * 1991-06-07 1994-09-15 Teikoku Seiyaku Kabushiki Kaisha Physiologically active polypeptide-containing pharmaceutical composition
HU227530B1 (en) * 1991-11-22 2011-07-28 Warner Chilcott Company Delayed-release compositions containing risedronate and process for their production
SE501389C2 (sv) * 1992-04-24 1995-01-30 Leiras Oy Farmaceutiskt preparat och förfarande för dess framställning
RU2068689C1 (ru) * 1992-09-24 1996-11-10 Товарищество с ограниченной ответственностью "Лекрон" Способ получения таблеток парацетамола
DE69332082T2 (de) * 1992-11-06 2003-02-06 Hisamitsu Pharmaceutical Co., Inc. Perorale pharmazeutische zubereitung mit freisetzung im unteren verfdauungstrakt
JPH06192107A (ja) 1992-12-25 1994-07-12 Sanwa Kagaku Kenkyusho Co Ltd グリチルリチン経口剤
GB9516268D0 (en) * 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon
GB9614235D0 (en) * 1996-07-06 1996-09-04 Danbiosyst Uk Composition for enhanced uptake of polar drugs from mucosal surfaces

Also Published As

Publication number Publication date
JP2002537321A (ja) 2002-11-05
CA2363123A1 (en) 2000-08-31
CA2363123C (en) 2011-09-06
JP5412491B2 (ja) 2014-02-12
DE60038097D1 (de) 2008-04-03
WO2000050012A1 (en) 2000-08-31
ES2301477T3 (es) 2008-07-01
EP1154761B1 (en) 2008-02-20
EP1154761A1 (en) 2001-11-21
DE60038097T2 (de) 2009-02-12
JP2012067115A (ja) 2012-04-05
ATE386508T1 (de) 2008-03-15

Similar Documents

Publication Publication Date Title
AU2681300A (en) Solid oral dosage form containing an enhancer
MY151458A (en) Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
WO2004012700A3 (en) Dosage form comprising high dose high soluble active ingredient as modified release and low dose active ingredient as immediate release
HUP0401963A3 (en) Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient
BR0010485A (pt) Formulações de derivados de eritromicina de liberação prolongada
AU1025795A (en) Prolineamide derivatives
CA2356380A1 (en) Immunosuppressive effects of pteridine derivatives
WO2002008217A3 (en) COUMARIN DERIVATIVES USEFUL AS TNFα INHIBITORS
AU2001278771A1 (en) Carboxylic acid derivatives, process for producing the same and drugs containingthe same as the active ingredient
EP0738152A1 (en) Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents
AU764280C (en) Process for the preparation of pellets with a content of up to 90 wt. per cent of a pharmaceutical active ingredient
TW280774B (https=)
CA2344053A1 (en) Composition containing cinnamic acid derivatives for preventing or treating elevated blood lipid level-related diseases
UA66812C2 (uk) Препаративна форма лікарського засобу із регульованим вивільненням активної речовини
HUP0203716A3 (en) Substituted n-benzyl-indol-3-yl glyoxylic acid derivatives having an anti-tumoral effect and pharmaceutical compositions containing them
CA2255052A1 (en) Sustained release preparation of prostaglandin i derivatives
AU5647199A (en) Carboxylic acid derivatives and drugs containing the same as the active ingredient
AU2001234107A1 (en) Benzoic acid derivatives, process for producing the same and drugs containing the same as the active ingredient
WO2005053660A3 (en) Pharmaceutical compositions comprising danazol
AU2001291731A1 (en) Pharmaceutical, effervescent formulation containing ramipril
WO2002006299A3 (en) Therapeutic uses for aminosterol compounds
WO2000064427A3 (en) Lamivudine containing pharmaceutical formulation
AU2001284476A1 (en) Novel crystals of 1,3,4-oxadiazole derivative, process for producing the crystals and medicines containing the same as the active ingredient
IL161768A0 (en) Carboxylic acid derivative compounds and drugs containing the same as the active ingredient
AU2827500A (en) Fluorinated chalcone derivatives or salts thereof and drugs containing the same as the active ingredient

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase